Translating ctDNA into cutaneous melanoma care: An international expert survey - PubMed

19 hours ago

International experts surveyed consider ctDNA most valuable for detecting minimal residual disease, surveillance of recurrence, and in stage IV melanoma.
Experts rated ctDNA superior to biomarkers S100 and LDH for early relapse detection and identifying progressive disease.
A majority (80%) agree ctDNA correlates with radiographic response, and 82% favor integrating it into routine follow-ups.
In urgent high-tumor-burden situations, many would initiate therapy based on ctDNA if tissue analysis is pending or unavailable.
For CNS lesions, blood ctDNA was less supported, but cerebrospinal fluid ctDNA was considered valuable by 66%.
Small to mid-size targeted panels and short turnaround times are preferred pragmatic approaches.
Major barriers to clinical implementation include the need for prospective trials, standardized guidelines, and reimbursement policies.
Overall, ctDNA is seen as a valuable adjunct in selected melanoma scenarios, requiring further validation and frameworks for broader use.

Hasty Briefsbeta